Email  |  BV_FTP  |  OA

Hotline:+86 27 8798 8585  CN   |   EN

CN   |   EN

Current location:Home >> Latest News >> Company News

BravoBio was Invited to "2022 China Nucleic Acid Drug and Neotype Vaccine Industrial Conference"

Author:博沃管理员    Release time:2022-08-25 10:30:00

On August 18-19th, the "2022 China Nucleic Acid Drug and Neotype Vaccine Industrial Conference" was successfully held by Taas Labs in Wuhan, China. Dr. Xu Long, Project Manager of BravoBio, attended the Conference and gave a keynote speech on "Development Strategy of a Novel Broad-Spectrum Coronavirus Vaccine" under "Domestic and International Vaccine Research and Development Progress".

图片

Focusing on the domains of nucleic acid drug and novel vaccine, the Conference integrated high-level resources in China and worldwide, and provided "ideological storms" by seizing the industry vane from professional and evolutionary perspectives. In the Conference, Dr. Xu gave an overview of the current R&D of COVID-19 vaccines, and expressed the necessity and urgency of developing a broad-spectrum coronavirus vaccine. Dr. Xu said, "though there are still major obstacles to developing a broad-spectrum coronavirus vaccine at this moment, with the commercialization of further cooperation and rapid development of upstream and downstream of the industrial chain, we are in the hope that a broad-spectrum coronavirus vaccine will be launched on the market in the near future and ultimately put an end to the COVID-19 pandemic."

图片